Pediatrix Medical Group, Inc. — Q1 2023 Form 10-Q
Business context and period. Unaudited results for the three months ended March 31, 2023, compared with Q1 2022. Pediatrix provides physician services focused on newborn, maternal-fetal, pediatric cardiology and other pediatric specialties; its affiliated physicians operate in 37 states. The company ceased Puerto Rico services on December 31, 2022.
Financial performance
| Metric | Q1 2023 | Q1 2022 |
|---|---|---|
| Net revenue | $491.0 million | $482.2 million |
| Income (loss) from operations | $30.0 million | $39.1 million |
| Operating margin | 6.1% | 8.1% |
| Net income (loss) attributable to Pediatrix | $14.2 million | $(21.2) million |
| Diluted EPS | $0.17 | $(0.25) |
| Adjusted EBITDA, non-GAAP | $40.1 million | $50.7 million |
| Adjusted EPS, non-GAAP | $0.23 | $0.33 |
| Cash from operating activities, continuing operations | $(100.6) million | $(89.9) million |
Revenue increased 1.8%; same-unit revenue rose 2.0%, including 1.6% growth from patient-service volumes and 0.4% from reimbursement-related factors. Net patient service revenue was $423.2 million, hospital contract administrative fees were $66.0 million, and other revenue was $1.8 million. Contracted managed care represented 67% of patient-service revenue and government payors 26%.
Practice salaries and benefits increased 5.6% to $362.2 million, driven mainly by higher clinical compensation. Practice supplies and other operating expenses increased 7.8% to $30.7 million. General and administrative expense declined to $59.1 million from $61.3 million, or 12.0% of revenue versus 12.7%. Higher operating costs and reduced CARES Act relief contributed to lower operating income and Adjusted EBITDA. Q1 2022 included $10.4 million of CARES Act relief and a $57.0 million loss on early debt extinguishment; Q1 2023 had neither item. Q1 2022 also included $1.4 million of restructuring expenses.
Liquidity, debt and balance sheet
- Cash and cash equivalents were $6.1 million at March 31, 2023, down from $9.8 million at year-end; short-term investments were $96.7 million.
- Management reported working capital of $124.4 million, versus $1.0 million at December 31, 2022, principally due to net line-of-credit borrowings.
- Debt principal totaled $751.5 million: $237.5 million under the Term A Loan, $114.0 million drawn on the revolver, and $400.0 million of 5.375% senior notes due 2030. The credit agreement matures in 2027; $336.0 million remained available. Balance-sheet debt and finance-lease liabilities, including current portions and net presentation, were approximately $658.6 million, in addition to the separately presented $114.0 million line of credit.
- Operating cash use was $100.6 million, reflecting in part the first-quarter payment of annual performance-based compensation. Net cash from financing was $108.6 million, primarily from $110.0 million of net revolver borrowings. Capital expenditures were $7.0 million.
- DSO improved to 51.1 days from 53.1 at December 31, 2022 and 59.2 at March 31, 2022. A 1 percentage-point interest-rate change on credit-agreement borrowings would affect annual pretax income by approximately $3.5 million.
Outlook, risks and other notable items
No specific revenue or earnings guidance is provided. Management expects operating cash generation, cash on hand and available credit to fund working capital, anticipated acquisitions and capital expenditures, share repurchases and obligations for at least the next 12 months. The company stated it was in material compliance with debt covenants at quarter-end and expected to remain compliant through 2023.
Key risks include lower reimbursement from government programs, shifts in payer mix, clinician compensation and other cost inflation, patient collection and bad-debt exposure, and uncertainty around the No Surprises Act and its independent dispute-resolution process. Management also notes healthcare regulatory changes and COVID-19 uncertainty. The company carries significant professional-liability exposure, including self-insured portions: the recorded professional-liability total was $295.0 million, with a related $50.1 million insurance receivable. Government audits and malpractice or other litigation could result in material adverse outcomes; liabilities beyond insurance coverage could be significant. The filing reports no material changes to risk factors in the 2022 Form 10-K.
On April 26, 2023, the company entered into amended employment agreements with its CEO, CFO and General Counsel, including specified salaries, incentive targets and severance provisions.
Important facts for investors to verify
- Whether revenue growth and improved collections can offset rising clinical compensation and other operating costs.
- Whether payer mix, reimbursement rates and No Surprises Act dispute outcomes affect realized revenue and margins.
- The sustainability of cash flow given first-quarter operating cash use, incentive-compensation payments and continued reliance on revolver borrowings.
- Debt covenant headroom, variable-rate exposure and the adequacy of professional-liability reserves and insurance.
- Underlying performance excluding prior-year CARES Act relief and debt-extinguishment costs; non-GAAP Adjusted EBITDA and Adjusted EPS are supplemental measures, not GAAP results.